PTC Therapeutics PTCT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Emflaza | $120.05M-39.2% | $146.36M-29.4% | $169.8M-24.2% | $186.58M-22.1% | $197.52M-23.4% | |
| Other Products | $37.42M-4.8% | $37.27M+0.9% | $34.56M-16.8% | $35.92M-6.0% | $39.29M+22.4% | |
| Translarna | -$125.81M— | -$98.63M— | —— | —— | —— | |
| Revenue by Geography | ||||||
| All Other Countries Other Than Russia Brazil And United States | $155.39M-20.8% | $168.41M-14.7% | $152.69M-32.2% | $165.78M-28.4% | $196.28M-17.4% | |
| BR | $97.37M+33.6% | $65.66M-8.9% | $63.46M-23.5% | $83.45M+22.0% | $72.88M+38.4% | |
| RU | $65.18M-28.6% | $100.45M-4.7% | $131.41M+70.2% | $107.26M+9.7% | $91.29M-22.0% | |
| US | $340.91M+72.6% | $252.18M+21.7% | $191.06M-13.3% | $186.58M-19.7% | $197.52M-20.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does PTC Therapeutics break its business down?
- PTC Therapeutics (PTCT) reports revenue by product across 6 parts — Emflaza, Other Products, Sephience, Translarna1 and Translarna. Each is extracted from the segment footnotes and tracked over time.
- Where does PTC Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in PTC Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
